Conviction
$ Value
$134.4M
Shares
8,398,438
Price
$16
Filed
Apr 20
▶ Why this score? (10/10)
- ✓ Open market buy (+3)
- ✓ Trade value >= $5.0M (+3)
- ✓ % of holdings >= 20% (+2)
- ✓ Director (+1)
- ✓ 10%+ owner (+1)
- ✓ Cluster: 3 insiders buying (+2)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
Kaplan Andrew T. / BAIN CAPITAL INVESTORS LLC
Title
—
CIK
0001752059
Roles
Transaction Details
Transaction Date
2026-04-20
Code
P
Table
Non-Derivative
Ownership
Indirect
Equity Swap
No
Shares After
26,255,581
Footnotes
Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. | The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Mr. Kaplan's continued service through each such vesting date. | Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus"). | Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Filing Info
Kaplan Andrew T. / BAIN CAPITAL INVESTORS LLC's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-20 | KLRA | C | — |
| 2026-04-20 | KLRA | ▲ | $134.4M ★ |
| 2026-04-20 | KLRA | C | $0 |
| 2026-04-16 | KLRA | A | $0 |
Other Insiders at KLRA (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC / Koppel Adam | $25.0M | — | 2026-04-20 |
| RTW INVESTMENTS, LP | $8.0M | — | 2026-04-20 |
| BAIN CAPITAL INVESTORS LLC | — | — | 2026-04-20 |
| MILLIGAN JOHN F | — | — | 2026-04-16 |
|
Renaud Ronald C JR
CEO & President
|
— | — | 2026-04-16 |
| MACKAY MARTIN | — | — | 2026-04-16 |
| Koppel Adam | — | — | 2026-04-20 |
|
Pagan Douglas W.
Chief Financial Officer
|
— | — | 2026-04-16 |
| Bain Capital Life Sciences Investors, LLC | — | — | 2026-04-20 |
|
Burgess Paul D.
See Remarks
|
— | — | 2026-04-16 |
|
Cloghessy Paula
Chief People Officer
|
— | — | 2026-04-16 |
| Kaplan Andrew T. | — | — | 2026-04-20 |
| Clyburn Frank | — | — | 2026-04-16 |
| Hite Christopher | — | — | 2026-04-16 |
|
Akamine Scott
Chief Legal Officer
|
— | — | 2026-04-16 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | — | — | 2026-04-20 |
|
Coleman Jamie Beth
Chief Commercial Officer
|
— | — | 2026-04-16 |
|
Wasserman Scott M.
Chief Medical Officer
|
— | — | 2026-04-16 |